These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 17660383

  • 1. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY.
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [Abstract] [Full Text] [Related]

  • 2. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 3. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 4. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro.
    Wu R, Ding W, Liu T, Zhu H, Hu Y, Yang B, He Q.
    Cancer Lett; 2009 Nov 18; 285(1):13-22. PubMed ID: 19647933
    [Abstract] [Full Text] [Related]

  • 5. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD.
    Clin Cancer Res; 2008 Oct 01; 14(19):6218-27. PubMed ID: 18829501
    [Abstract] [Full Text] [Related]

  • 6. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
    Chang JY, Chang CY, Kuo CC, Chen LT, Wein YS, Kuo YH.
    Mol Pharmacol; 2004 Jan 01; 65(1):77-84. PubMed ID: 14722239
    [Abstract] [Full Text] [Related]

  • 7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 8. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
    Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC, Guh JH.
    Biochem Pharmacol; 2007 Jun 30; 74(1):10-9. PubMed ID: 17475221
    [Abstract] [Full Text] [Related]

  • 9. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
    Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM.
    Cancer Res; 2007 Jun 15; 67(12):5865-71. PubMed ID: 17575155
    [Abstract] [Full Text] [Related]

  • 10. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
    Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC.
    Cancer Res; 2001 Jul 15; 61(14):5480-5. PubMed ID: 11454695
    [Abstract] [Full Text] [Related]

  • 11. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM.
    Cancer Res; 2003 Apr 15; 63(8):1838-45. PubMed ID: 12702571
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
    Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai NM, Chen SP, Chang WL, Harn HJ.
    Biochem Pharmacol; 2006 Jul 28; 72(3):308-19. PubMed ID: 16782069
    [Abstract] [Full Text] [Related]

  • 13. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
    Tsai AC, Wang CY, Liou JP, Pai HC, Hsiao CJ, Chang JY, Wang JC, Teng CM, Pan SL.
    Cell Death Dis; 2014 Apr 10; 5(4):e1162. PubMed ID: 24722287
    [Abstract] [Full Text] [Related]

  • 14. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz J, Wang LG, Perez-Soler R, Marcelli M, Bekesi G, Holland JF.
    Cancer Res; 2002 Nov 01; 62(21):6080-8. PubMed ID: 12414632
    [Abstract] [Full Text] [Related]

  • 15. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo.
    Hsu YL, Kuo PL, Tzeng TF, Sung SC, Yen MH, Lin LT, Lin CC.
    J Gastroenterol Hepatol; 2008 Jul 01; 23(7 Pt 2):e290-9. PubMed ID: 18522681
    [Abstract] [Full Text] [Related]

  • 16. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
    Qiao F, Zuo D, Shen X, Qi H, Wang H, Zhang W, Wu Y.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):259-70. PubMed ID: 22752214
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
    Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K.
    Cancer Res; 1997 Aug 01; 57(15):3208-13. PubMed ID: 9242451
    [Abstract] [Full Text] [Related]

  • 18. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
    Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F.
    Cancer Res; 2006 Jan 15; 66(2):951-9. PubMed ID: 16424030
    [Abstract] [Full Text] [Related]

  • 19. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
    Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, Zisterer DM.
    Mol Pharmacol; 2006 Jul 15; 70(1):60-70. PubMed ID: 16571652
    [Abstract] [Full Text] [Related]

  • 20. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):201-12. PubMed ID: 18350296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.